Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADG116 in advanced/metastatic solid tumors
NCT04501276Phase 1Completed
- Sponsor
- Adagene
- Start
- Sep 2020
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of adg116 in solid tumor (3 arms), sponsored by Adagene. Primary endpoints: Dose-Limiting Toxicities at 21 days and Adverse Events. Started Sep 2020; status: completed.
02
Drugs
adg116
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04501276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501276.